These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 21345300

  • 1. The 'head-to-head' comparison of etanercept and infliximab in treating children with juvenile idiopathic arthritis.
    Lamot L, Bukovac LT, Vidovic M, Frleta M, Harjacek M.
    Clin Exp Rheumatol; 2011; 29(1):131-9. PubMed ID: 21345300
    [Abstract] [Full Text] [Related]

  • 2. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study.
    Lahdenne P, Vähäsalo P, Honkanen V.
    Ann Rheum Dis; 2003 Mar; 62(3):245-7. PubMed ID: 12594111
    [Abstract] [Full Text] [Related]

  • 3. Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept.
    Katsicas MM, Russo RA.
    Clin Exp Rheumatol; 2005 Mar; 23(4):545-8. PubMed ID: 16095128
    [Abstract] [Full Text] [Related]

  • 4. Switching the therapy from etanercept to infliximab in a child with rheumatoid factor positive polyarticular juvenile idiopathic arthritis.
    Nerome Y, Imanaka H, Nonaka Y, Takei S.
    Mod Rheumatol; 2007 Mar; 17(6):526-8. PubMed ID: 18084710
    [Abstract] [Full Text] [Related]

  • 5. A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission.
    Pratsidou-Gertsi P, Trachana M, Pardalos G, Kanakoudi-Tsakalidou F.
    Clin Exp Rheumatol; 2010 Mar; 28(6):919-22. PubMed ID: 21205467
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.
    Horneff G, Foeldvari I, Minden K, Trauzeddel R, Kümmerle-Deschner JB, Tenbrock K, Ganser G, Huppertz HI.
    Arthritis Rheumatol; 2015 May; 67(8):2240-9. PubMed ID: 25891010
    [Abstract] [Full Text] [Related]

  • 7. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis.
    Tynjälä P, Lahdenne P, Vähäsalo P, Kautiainen H, Honkanen V.
    Ann Rheum Dis; 2006 Aug; 65(8):1044-9. PubMed ID: 16449314
    [Abstract] [Full Text] [Related]

  • 8. Long-term outcome of anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondyloarthritis.
    Hugle B, Burgos-Vargas R, Inman RD, O'Shea F, Laxer RM, Stimec J, Whitney-Mahoney K, Duvnjak M, Anderson M, Tse SM.
    Clin Exp Rheumatol; 2014 Aug; 32(3):424-31. PubMed ID: 24387974
    [Abstract] [Full Text] [Related]

  • 9. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Østergaard M, All Departments of Rheumatology in Denmark.
    Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
    [Abstract] [Full Text] [Related]

  • 10. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
    Buch MH, Bingham SJ, Bejarano V, Bryer D, White J, Reece R, Quinn M, Emery P.
    Arthritis Rheum; 2007 Apr 15; 57(3):448-53. PubMed ID: 17394231
    [Abstract] [Full Text] [Related]

  • 11. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
    Tynjälä P, Vähäsalo P, Honkanen V, Lahdenne P.
    Ann Rheum Dis; 2009 Apr 15; 68(4):552-7. PubMed ID: 18467515
    [Abstract] [Full Text] [Related]

  • 12. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
    Gerloni V, Pontikaki I, Gattinara M, Fantini F.
    Ann Rheum Dis; 2008 Aug 15; 67(8):1145-52. PubMed ID: 17981916
    [Abstract] [Full Text] [Related]

  • 13. [Biological therapy treatment of juvenile idiopathic arthritis].
    Herlin T.
    Ugeskr Laeger; 2008 Jun 09; 170(24):2105-8. PubMed ID: 18565289
    [Abstract] [Full Text] [Related]

  • 14. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry.
    Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, Dehoratius R, Kishimoto M, Kremer JM, CORRONA Investigators.
    Ann Rheum Dis; 2012 Jul 09; 71(7):1134-42. PubMed ID: 22294625
    [Abstract] [Full Text] [Related]

  • 15. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
    Lurati A, Pontikaki I, Teruzzi B, Desiati F, Gerloni V, Gattinara M, Cimaz R, Fantini F.
    Arthritis Rheum; 2006 May 09; 54(5):1602-7. PubMed ID: 16646003
    [Abstract] [Full Text] [Related]

  • 16. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, Koopman-Keemink Y, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW.
    JAMA; 2011 Dec 07; 306(21):2340-7. PubMed ID: 22056397
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.
    Windschall D, Horneff G.
    Clin Rheumatol; 2016 Dec 07; 35(12):2925-2931. PubMed ID: 27709443
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
    Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, Sibilia J, Koné-Paut I, Gandon-Laloum S, LeBideau M, Bader-Meunier B, Mouy R, Debré M, Landais P, Prieur AM.
    Arthritis Rheum; 2003 Apr 07; 48(4):1093-101. PubMed ID: 12687553
    [Abstract] [Full Text] [Related]

  • 19. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
    Otten MH, Prince FH, Twilt M, Ten Cate R, Armbrust W, Hoppenreijs EP, Koopman-Keemink Y, Wulffraat NM, Gorter SL, Dolman KM, Swart JF, van den Berg JM, van Rossum MA, van Suijlekom-Smit LW.
    J Rheumatol; 2011 Oct 07; 38(10):2258-63. PubMed ID: 21844151
    [Abstract] [Full Text] [Related]

  • 20. Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors.
    Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O'Neil KM, Zeft AS, Szer IS, Ringold S, Brunner HI, Schanberg LE, Sundel RP, Milojevic DS, Punaro MG, Chira P, Gottlieb BS, Higgins GC, Ilowite NT, Kimura Y, Johnson A, Huang B, Lovell DJ, Childhood Arthritis and Rheumatology Research Alliance (CARRA).
    J Rheumatol; 2014 Jun 07; 41(6):1163-70. PubMed ID: 24786928
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.